Trust Co. of Vermont Buys Shares of 116 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Defense World · Oct 3, 2022 19:02

Trust Co. of Vermont bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 116 shares of the pharmaceutical company's stock, valued at approximately $33,000.

A number of other hedge funds have also modified their holdings of the business. Procyon Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 2.8% during the 2nd quarter. Procyon Advisors LLC now owns 1,366 shares of the pharmaceutical company's stock worth $385,000 after purchasing an additional 37 shares in the last quarter. Nkcfo LLC increased its stake in shares of Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Nkcfo LLC now owns 8,515 shares of the pharmaceutical company's stock worth $2,399,000 after purchasing an additional 40 shares in the last quarter. J2 Capital Management Inc grew its stake in Vertex Pharmaceuticals by 2.2% in the 1st quarter. J2 Capital Management Inc now owns 1,915 shares of the pharmaceutical company's stock worth $500,000 after acquiring an additional 41 shares during the period. CHURCHILL MANAGEMENT Corp grew its stake in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 7,935 shares of the pharmaceutical company's stock worth $2,236,000 after acquiring an additional 42 shares during the period. Finally, Evoke Wealth LLC grew its stake in Vertex Pharmaceuticals by 32.8% in the 1st quarter. Evoke Wealth LLC now owns 174 shares of the pharmaceutical company's stock worth $45,000 after acquiring an additional 43 shares during the period. 91.33% of the stock is owned by hedge funds and other institutional investors.

Get Vertex Pharmaceuticals alerts:

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Argus lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a "buy" rating in a research note on Monday, June 13th. Cantor Fitzgerald assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, July 12th. They issued an "overweight" rating and a $365.00 target price for the company. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $291.00 to $307.00 and gave the stock an "overweight" rating in a research note on Friday, August 5th. HC Wainwright lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Friday, August 5th. Finally, Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $250.00 to $253.00 and gave the company an "equal weight" rating in a report on Monday, August 8th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $291.65.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $305.06, for a total value of $3,565,846.34. Following the transaction, the chief executive officer now owns 99,598 shares in the company, valued at approximately $30,383,365.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $305.06, for a total value of $3,565,846.34. Following the transaction, the chief executive officer now owns 99,598 shares in the company, valued at approximately $30,383,365.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Stuart A. Arbuckle sold 22,173 shares of the business's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $303.93, for a total transaction of $6,739,039.89. Following the completion of the sale, the chief operating officer now directly owns 45,278 shares of the company's stock, valued at approximately $13,761,342.54. The disclosure for this sale can be found here. Insiders have sold 196,831 shares of company stock worth $56,532,979 in the last quarter. 0.40% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $289.54 on Monday. The company has a current ratio of 4.50, a quick ratio of 4.36 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $74.26 billion, a price-to-earnings ratio of 23.41, a PEG ratio of 2.05 and a beta of 0.42. The firm's fifty day simple moving average is $287.25 and its 200 day simple moving average is $275.78. Vertex Pharmaceuticals Incorporated has a twelve month low of $176.36 and a twelve month high of $305.95.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.25 EPS for the quarter, topping analysts' consensus estimates of $3.05 by $0.20. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The firm had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the business posted $2.80 EPS. The firm's revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.67 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Trust Co. of Vermont Buys Shares of 116 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wall Street Analyst Weigh In

Insiders Place Their Bets

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals Profile

Further Reading

Risk Disclaimer